What is the role of antineoplastic drug safety in reimbursement decision making?
Rationale. From 2014 to 2017, the portion of antineoplastic drugs dossiers submitted to reimbursement in Russia has grown from 15% to 28%. This group of drugs is characterized by severe adverse events (Aes). The question whether drug safety is taken into consideration by decision makers is still ope...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2018-11-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/260 |